Source: Annual Congress 2003 - Models and markers of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. I. Zervou, E. G. Tzortzaki, K. Samara, E. Papadopouli, M. Plataki, M. Tsoumakidou, N. M. Siafakas (Heraklion, Greece). Genetic comparison between severe persistent asthma and COPD. Eur Respir J 2003; 22: Suppl. 45, 605

Member's Comments

No comment yet.

Related content which might interest you: Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Identifying asthma features in severe COPD Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS) Year: 2018 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Ykl-40 and phenotyping of severe asthma Source: International Congress 2019 – Immunopathological mechanisms of lung disease Year: 2019 The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Phenotypic predictors of chronic obstructive pulmonary disease exacerbations in the BIOAIR study Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Difficulty in management of COPD exacerbation: Is this chronic exacerbation or difficult COPD: “A specific phenotype?” Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Localization of respiratory viral antigens in patients with exacerbations of non allergic late-onset asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 411s Year: 2004 Mechanisms in COPD compared with asthma Source: Breathe 2008; 5: 134-144 Year: 2008 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Factors associated with exacerbation in a general practitioners’-based Swiss chronic obstructive pulmonary disease (COPD) cohort Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Phenotypic markers of asthma and COPD at the tissue level Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Incidence of COPD and asthma overlap Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017